MarketLens
Sign Up

What's Driving Axsome Therapeutics' Recent Bull Run

6 months ago
SHARE THIS ON:

What's Driving Axsome Therapeutics' Recent Bull Run

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News3 days ago

Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week

Amylyx Pharmaceuticals shares rose nearly 79% this week after analysts raised price targets and the company launched a new capital raise, signaling renewed investor confidence.
Stock News1 week ago

This LSD-Based Drug Just Scored Again. Definium Stock Soars.

Definium Therapeutics' stock surged after the second positive Phase 3 study for its LSD-based drug, reinforcing the therapy's efficacy and boosting its regulatory path.
Stock News1 months ago

Why Is Neuronetics Stock Soaring Monday?

Neuronetics (STIM) shares rose sharply Monday after BTIG initiated coverage, citing a pivotal new phase as the psilocybin opportunity takes center stage.
Stock News1 months ago

Why Axsome Stock Has Doubled In Nine Months

Axsome Therapeutics stock has doubled in nine months, driven by its growing pipeline and positive developments in its drug candidates.

Breaking News

View All →

Top Headlines

View More →
Stock News48 minutes ago

Between Amazon, Alphabet, and Meta, Microsoft is Most Likely to Deliver Best Free Cash Flow in 2026

Stock News49 minutes ago

Amazon Web Services Backlog Reaches $496 Billion: Does That Make Amazon Stock a No Brainer Buy?

Stock News1 hour ago

Micron (MU) Falls More Steeply Than Broader Market: What Investors Need to Know

Stock News1 hour ago

Nvidia's $20 Billion Groq Bet Is Going Live Before the End of 2026. Here's What It Means for Investors.

Stock News1 hour ago

Q2 Earnings Season Winds Down: 3 Companies That Broke Records